Disease · MONDO_0005155
Comparisons in its trials57
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 57
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Cenicriviroc 150 mg vs Placebo: deaths from any cause | 6 of 1,185 | 2 of 593 | 1,778 | NCT03028740 | Trial comparisons |
| Cenicriviroc 150 mg vs Placebo: serious adverse events | 159 of 1,180 | 70 of 589 | 1,769 | NCT03028740 | Trial comparisons |
| Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Serious Adverse Events | 175 of 517 | 155 of 533 | 1,050 | NCT00006164 | Trial comparisons |
| Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Development of Hepatocellular Carcinoma (HCC) | 13 of 517 | 16 of 533 | 1,050 | NCT00006164 | Trial comparisons |
| Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Variceal Hemorrhage | 5 of 517 | 11 of 533 | 1,050 | NCT00006164 | Trial comparisons |
| Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Ascites | 32 of 517 | 27 of 533 | 1,050 | NCT00006164 | Trial comparisons |
| Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Presumed Hepatocellular Carcinoma (HCC) | 10 of 517 | 9 of 533 | 1,050 | NCT00006164 | Trial comparisons |
| Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Death From Any Cause | 31 of 517 | 22 of 533 | 1,050 | NCT00006164 | Trial comparisons |
| Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Spontaneous Bacterial Peritonitis | 3 of 517 | 3 of 533 | 1,050 | NCT00006164 | Trial comparisons |
| Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Child-Turcotte-Pugh (CTP) Score of 7 or Higher at Two Consecutive Study Visits | 57 of 517 | 52 of 533 | 1,050 | NCT00006164 | Trial comparisons |
| Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Hepatic Encephalopathy | 15 of 517 | 22 of 533 | 1,050 | NCT00006164 | Trial comparisons |
Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Progression of Liver Disease as Indicated by Death, Hepatic Decompensation, Hepatocellular Carcinoma, or for Patients With Noncirrhotic Fibrosis at Baseline, an Increase in the Ishak Hepatic Fibrosis Score of 2 or More Points | 157 of 517 | 157 of 533 | 1,050 | NCT00006164 | Trial comparisons |
| Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: serious adverse events | 175 of 517 | 155 of 533 | 1,050 | NCT00006164 | Trial comparisons |
| PegIntron vs Untreated Control: serious adverse events | 93 of 311 | 74 of 315 | 626 | NCT00048724 | Trial comparisons |
| Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Increase in Ishak Fibrosis Score by 2 Points or More at 2 or 4 Year Biopsies | 71 of 273 | 81 of 274 | 547 | NCT00006164 | Trial comparisons |
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks vs ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks: serious adverse events | 13 of 208 | 7 of 172 | 380 | NCT01704755 | Trial comparisons |
| CVC 150 mg vs Placebo: Number of Participants With Complete Resolution of Steatohepatitis With no Concurrent Worsening of Fibrosis Stage at Year 1 | 11 of 145 | 8 of 144 | 289 | NCT02217475 | Trial comparisons |
CVC 150 mg vs Placebo: Number of Participant With Hepatic Histological Improvement in NAS by ≥ 2 Points With at Least 1-Point Reduction in Either Lobular Inflammation or Hepatocellular Ballooning and no Concurrent Worsening of Fibrosis at Year 1 | 23 of 145 | 27 of 144 | 289 | NCT02217475 | Trial comparisons |
CVC 150 mg vs Placebo: Number of Participants With Complete Resolution of Steatohepatitis With no Concurrent Worsening of Fibrosis Stage and Improvement in Fibrosis by at Least 1 Stage (NASH CRN System) and no Worsening of Steatohepatitis at Year 1 | 7 of 145 | 4 of 144 | 289 | NCT02217475 | Trial comparisons |
| CVC 150 mg vs Placebo: Number of Participants With Improvement in Fibrosis by at Least 1 Stage (NASH CRN System) and no Worsening of Steatohepatitis at Year 1 | 29 of 145 | 15 of 144 | 289 | NCT02217475 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005155/comparisons